Ubs Group Ag Erytech Pharma S.A. Transaction History

Ubs Group Ag

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.34 - $1.38 $1,429 - $5,802	-4,205 Reduced 88.43%	550 $0
Q4 2022 Feb 08, 2023	BUY	$0.33 - $0.68 $143 - $295	435 Added 10.07%	4,755 $1,000
Q3 2022 Nov 10, 2022	SELL	$0.6 - $1.31 $2,634 - $5,752	-4,391 Reduced 50.41%	4,320 $2,000
Q2 2022 Aug 10, 2022	BUY	$1.03 - $1.8 $8,972 - $15,679	8,711 New	8,711 $10,000
Q1 2022 May 16, 2022	SELL	$1.36 - $2.35 $4,872 - $8,420	-3,583 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.15 - $6.21 $7,703 - $22,250	3,583 New	3,583 $8,000
Q4 2018 Feb 14, 2019	SELL	$5.54 - $9.23 $6,902 - $11,500	-1,246 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$8.57 - $11.41 $599 - $798	70 Added 5.95%	1,246 $11,000
Q2 2018 Aug 14, 2018	SELL	$11.17 - $21.41 $11 - $21	-1 Reduced 0.08%	1,176 $13,000
Q1 2018 May 15, 2018	SELL	$20.0 - $23.28 $9,200 - $10,708	-460 Reduced 28.1%	1,177 $25,000
Q4 2017 Feb 14, 2018	BUY	$17.93 - $30.3 $29,351 - $49,601	1,637	1,637 $36,000

Ticker ERYP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,018,600
Market Cap $16.8M
Description
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.